Vaxart Expands Intellectual Property Portfolio with European Patent Protecting Proprietary Norovirus Vaccine Technology

Vaxart Provides Business Update and Reports Second Quarter 2026 Financial Results

Vaxart to Host Stockholder Fireside Chat on August 7 at 4:30 p.m. ET

Vaxart Announces Results of Annual Meeting of Stockholders

Vaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 Vaccine

Vaxart Enters Cooperation Agreement with Stockholder Group and Announces Board and Corporate Governance Enhancements

Vaxart Publishes Presentation Urging Shareholders to Vote “FOR” ALL Six of the Company’s Highly Qualified Director Nominees on the WHITE Proxy Card TODAY

Vaxart’s Two Newest Independent Directors James Breitmeyer, M.D., Ph.D., and Kevin Finney Send Letter to Shareholders Ahead of 2026 Annual Meeting

Vaxart Urges Shareholders to Vote “FOR” ALL Six of the Company’s Highly Qualified Director Nominees on the WHITE Proxy Card TODAY

Vaxart Files Definitive Proxy Statement and Mails Letter to Shareholders